Profil
Inez de Greef-van der Sand has a current job as the Chief Executive Officer at DegenRx BV.
Aktive Positionen von Inez de Greef-van der Sand
| Unternehmen | Position | Beginn |
|---|---|---|
DegenRx BV
 DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Vorstandsvorsitzender | 01.09.2020 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
DegenRx BV
DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Health Technology |
